

Austin, TX; have been added as parties to this venture. Also, VLSI Technology, Inc., San Jose, CA; and Kyrel EMS Oyj, Kyroskoski, FINLAND have been dropped as parties to this venture. IMC, Linköping, SWEDEN has changed its name to Acreo.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and HDP User Group International, Inc. intends to file additional written notification disclosing all changes in membership.

On September 14, 1994, HDP User Group International, Inc. filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on March 23, 1995 (60 FR 15306).

The last notification was filed with the Department on August 31, 1999. A notice has not yet been published in the **Federal Register**.

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 00-20894 Filed 8-16-00; 8:45 am]

BILLING CODE 4410-11-M

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Advancement of In Situ Bioremediation Technologies

Notice is hereby given that, on February 14, 2000, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), Advancement of *In Situ* Bioremediation Technologies has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership status. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, ICI, Americas, Inc., Wilmington, DE and Beak International, Inc. which since has been acquired by GeoSyntec Consultants, Inc., Boca Raton, FL have been added as parties to this venture. Monsanto Company, St. Louis, MO has been dropped as a party to this venture. Also, Ciba Geigy Corporation, Ardsley, NY has changed its name to Ciba Specialty Chemicals, Toms River, NJ.

No other changes have been made in either the membership or planned

activity of the group research project. Membership in this group research project remains open, and Advancement of *In Situ* Bioremediation Technologies intends to file additional written notification disclosing all changes in membership.

On December 13, 1994, Advancement of *In Situ* Bioremediation Technologies filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on February 7, 1995 (60 FR 7214).

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 00-20891 Filed 8-16-00; 8:45 am]

BILLING CODE 4410-11-M

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—International Pharmaceutical Aerosol Consortium for Toxicology Testing of HFA-227 (IPACT-II)

Notice is hereby given that, on March 15, 2000, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), International Pharmaceutical Aerosol Consortium for Toxicology Testing of HFA-227 (IPACT-II) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership status. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Astra AB, a party to IPACT-II, changed its name to AstraZeneca AB, Sodertälje, SWEDEN; and Rhone-Poulenc Rorer Pharmaceuticals, Inc. and Hoechst Aktiengesellschaft, each a party to IPACT-II, changed their names to Aventis Pharma AG, Frankfurt am Main, GERMANY as the result of a corporate merger between their respective holding companies. The membership interest of Fisons plc in IPACT-II also has been transferred to Aventis Pharma AG as a result of this merger.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and International Pharmaceutical Aerosol Consortium for Toxicology Testing of HFA-227

(IPACT-II) intends to file additional written notification disclosing all changes in membership.

On February 21, 1991, International Pharmaceutical Aerosol Consortium for Toxicology Testing of HFA-227 (IPACT-II) filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on April 2, 1991 (56 FR 13489).

The last notification was filed with the Department on March 6, 1997. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on April 3, 1997 (62 FR 15939).

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 00-20892 Filed 8-16-00; 8:45 am]

BILLING CODE 4410-11-M

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—International Pharmaceutical Aerosol Consortium for Toxicology Testing of HFR-134a (IPACT-I)

Notice is hereby given that, on March 15, 2000, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), International Pharmaceutical Aerosol Consortium for Toxicology Testing of HFR-134a (IPACT-I) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership status. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Astra AB, a party to IPACT-I, changed its name to AstraZeneca AB, Sodertälje, SWEDEN; and Rhone-Poulenc Rorer Pharmaceuticals, Inc., a party to IPACT-I, changed its name to Aventis Pharma AG, Frankfurt am Main, GERMANY as a result of a corporate merger involving its holding company. The membership interest of Fisons plc in IPACT-I also has been transferred to Aventis Pharma AG as a result of the merger.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and International Pharmaceutical Aerosol Consortium for Toxicology Testing of HFA-134a